Neuroma

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Retrieved on: 
Thursday, January 18, 2024

ALACHUA, Fla. and TAMPA, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value

Key Points: 
  • REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12.
  • Axoguard Nerve Cap demonstrated statistical superiority vs. standard-of-care neurectomy in the reduction of total pain reported by participants over the course of follow-up.
  • ALACHUA, Fla. and TAMPA, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap.
  • The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value

Bell Law Firm Secures $4M for Georgia Woman Following Medical Negligence

Retrieved on: 
Tuesday, May 30, 2023

Examinations that followed revealed pain to Ms. Perron’s distal lateral ankle with fibula, mild pain to the lateral ankle, ecchymosis, and edema.

Key Points: 
  • Examinations that followed revealed pain to Ms. Perron’s distal lateral ankle with fibula, mild pain to the lateral ankle, ecchymosis, and edema.
  • “This is why we trust juries,” stated Lloyd Bell, founding partner at Bell Law Firm.
  • We hope the jury’s decision provides Christine peace and closure as she moves forward.”
    Lloyd Bell has over 30 years of trial experience and has recovered hundreds of millions for medical negligence victims, including a record $75M medical malpractice verdict – the largest in Georgia history.
  • If you believe you have a medical malpractice case, contact Bell Law Firm today for a free consultation.

Axogen to Participate at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 3, 2022

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, and Peter Mariani, executive vice president and CFO will participate in upcoming investor conferences in November and December.

Key Points: 
  • ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, and Peter Mariani, executive vice president and CFO will participate in upcoming investor conferences in November and December.
  • Zaderej will participate in a fireside chat at the Jefferies London Healthcare Conference, on Tuesday, November 15, 2022 at 10:20 a.m. GMT, (5:20 a.m.
  • Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022

Retrieved on: 
Thursday, October 20, 2022

Axogen management will host an investment-community conference call and webcast at 8:00 a.m.

Key Points: 
  • Axogen management will host an investment-community conference call and webcast at 8:00 a.m.
  • Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves.
  • The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand

Retrieved on: 
Thursday, September 22, 2022

Surgeons in attendance will have the opportunity to meet and participate in hands-on demonstrations with Axogen staff, clinicians, and other experts at Booth #815 in the Solutions Center (exhibit hall).

Key Points: 
  • Surgeons in attendance will have the opportunity to meet and participate in hands-on demonstrations with Axogen staff, clinicians, and other experts at Booth #815 in the Solutions Center (exhibit hall).
  • We look forward to meeting and connecting with hand surgeons during our symposium and at our booth, said Karen Zaderej, chairman, CEO, and president of Axogen.
  • The American Society for Surgery of the Hand is the oldest medical society dedicated to the hand and upper extremity.
  • The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference

Retrieved on: 
Friday, July 29, 2022

Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at Canaccord Genuity's 42nd Annual Growth Conference in Boston.

Key Points: 
  • Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at Canaccord Genuity's 42nd Annual Growth Conference in Boston.
  • The presentation is scheduled for Wednesday, August 10, 2022, at 12:30 p.m.
  • Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance

Retrieved on: 
Monday, July 18, 2022

ALACHUA, Fla. and TAMPA, Fla., July 18, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced organizational updates and preliminary second quarter revenue.

Key Points: 
  • We are pleased with our performance in the second quarter, and we are encouraged by the strong underlying demand for our products.
  • Company is reaffirming its full-year 2022 financial guidance of revenue between $135 and $142 million, and gross margin above 80%.
  • The company will provide further business updates, along with its second quarter 2022 financial results, on Wednesday, August 3, 2022, after the market close.
  • The company will report second quarter 2022 financial results on Wednesday, August 3, 2022 after the market close.

Axogen, Inc. Appoints William Burke to Board of Directors

Retrieved on: 
Monday, July 11, 2022

Bill is an excellent addition to our board and brings a depth of finance, business development, and investor relations experience, commented Karen Zaderej, chairman, CEO, and president.

Key Points: 
  • Bill is an excellent addition to our board and brings a depth of finance, business development, and investor relations experience, commented Karen Zaderej, chairman, CEO, and president.
  • Burke was the executive vice president, chief financial officer of Haemonetics Corporation from August 2016 to June 2022 with responsibility for the global finance organization including investor relations.
  • He currently serves on the board of directors of MiroMatrix (NASDAQ CM: MIRO).
  • I am honored to join the Axogen Board of Directors and contribute to the companys mission of returning nerve function and quality of life to patients with peripheral nerve injuries, said Burke.

Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference

Retrieved on: 
Wednesday, May 18, 2022

Mariani will present at the Jefferies Virtual Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m.

Key Points: 
  • Mariani will present at the Jefferies Virtual Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m.
  • Zaderej will present at the JMP Securities Life Sciences Conference in New York City on Thursday, June 15, 2022 at 9:30 a.m.
  • Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft

Retrieved on: 
Wednesday, May 4, 2022

RECON is a multicenter, prospective, randomized, subject and evaluator blinded comparative clinical study of nerve cuffs (manufactured conduits) and Avance Nerve Graft, evaluating recovery outcomes for the repair of nerve discontinuities.

Key Points: 
  • RECON is a multicenter, prospective, randomized, subject and evaluator blinded comparative clinical study of nerve cuffs (manufactured conduits) and Avance Nerve Graft, evaluating recovery outcomes for the repair of nerve discontinuities.
  • The phase 3 pivotal study is designed to test for non-inferiority between the static two-point discrimination outcomes for Avance Nerve Graft and manufactured conduit.
  • The study design also allows for a sequential test for superiority of Avance Nerve Graft, following the non-inferiority analysis.
  • Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site.